I hold a (for me) large position in RVX and have a position in Zenith as well because I think there is a good chance apabetalone "works", will save lives and prolong quality of life.  IMO it is therefore worth a multiple of Friday's closing price for RVX (and for Zenith as well).  There is also a chance it could be a blockbuster.

At this point and through results (Year-end) I would not want to be out of either stock, much less short.  But I would certainly not bet the house payment.

There is also a decent chance that an SSRA could find a need to boost the sample size and cause significant delay.  If the SSRA has been canceled I would conclude that is good news.